Is Microsoft an Undervalued Growth Stock to Buy?
Tech giant Microsoft (NASDAQ:MSFT) has been one of the biggest…
Sell
18
DNLI Quote, Financials, Valuation and Earnings
Last price:
$20.61
Seasonality move
:
-14.4%
Day range:
$20.50 - $21.63
52-week range:
$14.56 - $33.33
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.46x
P/B ratio:
2.25x
Volume:
602.2K
Avg. volume:
935.8K
1-year change:
-7.2%
Market cap:
$3B
Revenue:
$330.5M
EPS (TTM):
-$2.76
Analysts' Opinion
-
Consensus RatingDenali Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $42.77, Denali Therapeutics has an estimated upside of 107.52% from its current price of $20.61.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $28.00 representing 100% downside risk from its current price of $20.61.
Fair Value
-
According to the consensus of 12 analysts, Denali Therapeutics has 107.52% upside to fair value with a price target of $42.77 per share.
DNLI vs. S&P 500
-
Over the past 5 trading days, Denali Therapeutics has underperformed the S&P 500 by -4.74% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Denali Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Denali Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Denali Therapeutics reported revenues of --.
Earnings Growth
-
Denali Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Denali Therapeutics reported earnings per share of -$0.63.
Enterprise value:
2.1B
EV / Invested capital:
--
Price / LTM sales:
9.46x
EV / EBIT:
--
EV / Revenue:
6.25x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-5.67x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $110.7M | $340.8M | -- | $1.3M | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$312.5M | -$169.5M | -$504.6M | -$113.8M | -$123.2M | |
| EBITDA | -$304.1M | -$150.8M | -$496.1M | -$111.6M | -$120.9M | |
| Diluted EPS | -$2.47 | -$0.97 | -$2.76 | -$0.72 | -$0.63 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $970.9M | $1.1B | $1.1B | $1.1B | $868.8M | |
| Total Assets | $1.1B | $1.4B | $1.2B | $1.2B | $1.5B | |
| Current Liabilities | $105.4M | $54.3M | $360.7M | $71.2M | $87.1M | |
| Total Liabilities | $187.8M | $437.7M | $416.3M | $118.4M | $135.5M | |
| Total Equity | $882.6M | $1B | $811.3M | $1.1B | $1.3B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$237.5M | -$332M | -$362.6M | -$87.4M | -$59.1M | |
| Cash From Investing | -$54.6M | $48.7M | -$187.9M | $100.9M | $93.7M | |
| Cash From Financing | $16.2M | $312.8M | $493.2M | $2.5M | -$18.6M | |
| Free Cash Flow | -$253.6M | -$347.6M | -$375.7M | -$89.4M | -$63M | |
DNLI
Sector
Market Cap
$3B
$45.9M
Price % of 52-Week High
61.84%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-7.2%
-32.15%
Beta (5-Year)
1.351
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$21.40
200-day SMA
Sell
Level
$23.05
Bollinger Bands (100)
Sell
Level
23.11 - 28.65
Chaikin Money Flow
Buy
Level
12.6M
20-day SMA
Sell
Level
$23.04
Relative Strength Index (RSI14)
Sell
Level
30.74
ADX Line
Buy
Level
12.14
Williams %R
Buy
Level
-97.891
50-day SMA
Sell
Level
$25.37
MACD (12, 26)
Sell
Level
-1.33
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Sell
Level
-5.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (13.8862)
Buy
CA Score
(Annual)
Level (0.3011)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-0.1504)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Stock Forecast FAQ
In the current month, DNLI has received 11 Buy ratings 1 Hold ratings, and 0 Sell ratings. The DNLI average analyst price target in the past 3 months is $42.77.
-
Where Will Denali Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Denali Therapeutics share price will rise to $42.77 per share over the next 12 months.
-
What Do Analysts Say About Denali Therapeutics?
Analysts are divided on their view about Denali Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Denali Therapeutics is a Sell and believe this share price will drop from its current level to $28.00.
-
What Is Denali Therapeutics's Price Target?
The price target for Denali Therapeutics over the next 1-year time period is forecast to be $42.77 according to 12 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is DNLI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Denali Therapeutics is a Buy. 11 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DNLI?
You can purchase shares of Denali Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Denali Therapeutics shares.
-
What Is The Denali Therapeutics Share Price Today?
Denali Therapeutics was last trading at $20.61 per share. This represents the most recent stock quote for Denali Therapeutics. Yesterday, Denali Therapeutics closed at $20.61 per share.
-
How To Buy Denali Therapeutics Stock Online?
In order to purchase Denali Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Sell
50
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
63
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
